Antimicrobial Peptides Market Size, Share, Growth, and Industry Analysis, By Type (Recombinant, Natural), By Application (Pharmaceutical, Animal Feed, Food Additive, Agriculture, Cosmetics, Others), Regional Insights and Forecast from 2026 to 2035

•   
•   
  

  Download Free Sample to learn more about this report

    

ANTIMICROBIAL PEPTIDES MARKET OVERVIEW

The global Antimicrobial peptides market size estimated at USD 0.55 billion in 2026 and is projected to reach USD 2.63 billion by 2035, growing at a CAGR of 19.08% from 2026 to 2035.

The Antimicrobial peptides market is expanding as peptide-based solutions gain importance against drug-resistant microorganisms, with antimicrobial peptides typically containing short amino-acid sequences and demonstrating activity against bacteria, fungi, viruses, and selected parasites. In 2023, approximately 1 in 6 laboratory-confirmed bacterial infections globally showed antibiotic resistance, increasing demand for alternative antimicrobial mechanisms. The Antimicrobial peptides market includes natural, recombinant, and synthetic peptide platforms used in pharmaceuticals, animal feed, food preservation, agriculture, and cosmetics. North America represented 38.61% of the global market in 2025, while pharmaceutical applications represented 52.26%. AI-assisted discovery, peptide engineering, membrane-targeting mechanisms, and biofilm control are strengthening commercial research activity.

The USA represents the largest national contributor to the Antimicrobial peptides market, supported by advanced biotechnology infrastructure, pharmaceutical research capacity, and antimicrobial-resistance programs. In 2024, the United States maintained extensive research activity involving peptide therapeutics, antimicrobial discovery, and synthetic biology. Federal antimicrobial-resistance initiatives have supported more than $2.7 billion in cumulative investment across antimicrobial products and development programs. The U.S. market benefits from strong demand for hospital infection control, wound-care technologies, biotechnology research, and veterinary applications. Approximately 38.61% of the global Antimicrobial peptides market was attributed to North America in 2025, with the United States accounting for the dominant regional share.

KEY FINDINGS

LATEST TRENDS

The Antimicrobial peptides market is increasingly shaped by AI-assisted discovery, peptide engineering, biofilm targeting, and resistance-aware therapeutic design. In 2024, an AI-based antimicrobial peptide platform generated 18 candidate sequences and reported a 94.4% positive validation rate, demonstrating how machine learning can accelerate early-stage screening. Another 2023 research platform used deep learning to design thousands of peptides, selected 500 candidates for laboratory screening, and identified 30 functional antimicrobial peptides. Six candidates demonstrated broad-spectrum activity against multidrug-resistant pathogens without observed development of bacterial resistance during the reported testing. These developments are shifting research from conventional natural-product screening toward computationally guided peptide optimization.

A second major trend is the development of stable peptides capable of retaining activity under physiological conditions. A 2024 study reported a modified peptide with broad-spectrum activity, biofilm activity, serum stability, and activity against colistin-resistant bacteria. The use of noncanonical amino acids is becoming important because peptide sequence modifications can improve stability, selectivity, and resistance to enzymatic degradation. Topical formulations, wound care, medical-device coatings, respiratory delivery, and localized infection control are receiving increasing attention because localized delivery can reduce systemic exposure. The Antimicrobial peptides market is therefore moving toward multifunctional molecules that combine antimicrobial action with anti-inflammatory, immunomodulatory, or biofilm-disrupting properties.

MARKET DYNAMICS

Driver

Rising demand for alternatives to conventional antibiotics.

Antimicrobial resistance is the primary driver of the Antimicrobial peptides market, with bacterial antimicrobial resistance associated with more than 4.7 million deaths globally in 2021. Approximately 1 in 6 laboratory-confirmed bacterial infections showed resistance in 2023, highlighting the shrinking effectiveness of established treatments. Antimicrobial peptides offer several mechanisms that differ from traditional antibiotic targets, including membrane disruption, intracellular interference, immune modulation, and biofilm disruption. Research published in 2024 also demonstrated that engineered peptides can remain active against resistant organisms, including colistin-resistant bacteria.

Drivers Impact Analysis*

Restraint

Peptide instability and difficult systemic delivery.

Peptide instability remains a major restraint because enzymatic degradation can reduce antimicrobial activity before the active molecule reaches the intended infection site. Approximately 34% of development concerns can be associated with stability and formulation challenges, while approximately 28% relate to delivery limitations in market-development assessments. Many peptide candidates also require specialized storage, purification, formulation, or administration technologies. Systemic use introduces additional concerns involving plasma stability, tissue distribution, renal clearance, immunogenicity, and toxicity.

Restraints Impact Analysis*

AI-guided peptide discovery and precision antimicrobial design

Opportunity

Artificial intelligence is creating a major opportunity for the Antimicrobial peptides market by accelerating candidate identification and sequence optimization. In 2024, one foundation-model approach generated 18 antimicrobial peptide candidates within 11 days and reported a 94.4% positive validation rate.

Two candidates demonstrated approximately 100-fold bacterial-load reduction in a reported animal infection model. Another 2023 study combined deep learning with cell-free biosynthesis, screening 500 computationally selected candidates and identifying 30 functional peptides, including 6 candidates with broad-spectrum activity against multidrug-resistant pathogens.

Translating laboratory efficacy into scalable commercial products

Challenge

Clinical translation remains a significant challenge because strong in-vitro antimicrobial activity does not automatically produce effective human therapy. Approximately 21% of development concerns can be associated with toxicity, hemolysis, or selectivity, while additional challenges involve pharmacokinetics, manufacturing consistency, formulation, and regulatory validation.

Peptides must demonstrate acceptable activity in biological environments containing serum proteins, enzymes, salts, and competing molecules. Manufacturing also requires consistent sequence purity and control of impurities. Commercial production becomes more complicated when peptides contain modified amino acids or complex structural features.

•   
•   
  

  Download Free Sample to learn more about this report

    

ANTIMICROBIAL PEPTIDES MARKET SEGMENTATION

By Type

Based on type the market can be categorized into Recombinant, Natural

• Recombinant: Recombinant antimicrobial peptides are gaining importance because controlled biological production can improve sequence consistency, reproducibility, and scalability. Recombinant systems can use microbial, yeast, or other biological hosts to produce specific peptide sequences under controlled conditions. The recombinant segment is estimated to represent approximately 61% of the specified two-type market allocation used in this analysis, reflecting strong demand from pharmaceutical research and industrial peptide production. Recombinant technologies are particularly relevant when natural extraction produces insufficient quantities or inconsistent purity.

• Natural: Natural antimicrobial peptides originate from organisms including plants, animals, insects, microorganisms, and marine species. Natural-source peptides represented 38% of the Antimicrobial peptides market in 2025, demonstrating the continuing importance of biological discovery. Natural peptides provide a large molecular library for identifying antimicrobial mechanisms that have evolved through host defense systems. Plant defensins, insect peptides, mammalian cathelicidins, bacterial bacteriocins, and marine-derived antimicrobial proteins are among the important research categories. Natural peptides can also provide templates for synthetic optimization, allowing researchers to modify amino-acid sequences to improve stability and reduce toxicity.

By Application

Based on application the market can be categorized into Pharmaceutical, Animal Feed, Food Additive, Agriculture, Cosmetics, Others

• Pharmaceutical: Pharmaceutical applications represented 52% of the Antimicrobial peptides market in 2025, making this the largest application segment. Demand is supported by antimicrobial resistance, hospital-acquired infections, wound infections, respiratory infections, and the need for new mechanisms against resistant pathogens. Peptide-based therapeutics are being investigated for topical, inhaled, injectable, and localized treatment. Research also focuses on combining antimicrobial peptides with established antibiotics to enhance bacterial susceptibility. Peptide engineering can improve serum stability and reduce hemolysis, while targeted delivery may increase local concentration at infection sites.

• Animal Feed: Animal-feed applications are supported by the need to reduce dependence on conventional antibiotics in livestock and poultry production. Antimicrobial peptides can provide alternative approaches for controlling bacterial populations and supporting animal health. The segment is estimated to represent approximately 13% of application activity in the specified market structure. Research focuses on bacteriocins, defensins, and engineered peptides that can remain functional in gastrointestinal conditions. Feed additives must demonstrate stability, safety, digestibility, and consistent antimicrobial performance. Demand is also influenced by antimicrobial stewardship policies and restrictions on antibiotic growth-promotion practices.

• Food Additive: Food-additive applications use antimicrobial peptides to control spoilage organisms and selected foodborne pathogens. This segment is estimated to account for approximately 9% of application activity. Natural bacteriocins and peptide-derived preservatives are attractive because they can provide targeted microbial inhibition while supporting clean-label preservation strategies. Food manufacturers evaluate peptide stability under different temperatures, pH conditions, salt concentrations, and processing environments. Antimicrobial peptides can be incorporated into coatings, packaging systems, or directly into selected food formulations.

• Agriculture: Agriculture represents an emerging application area for antimicrobial peptides, with approximately 8% of application activity attributed to agricultural uses in the specified market structure. Peptides are being evaluated against bacterial and fungal plant pathogens, including organisms that are difficult to control through conventional methods. Targeted antimicrobial peptides can potentially reduce dependence on broad-spectrum chemical treatments. Research involving citrus greening has investigated specifically targeted antimicrobial peptides designed to interact with essential bacterial proteins. Agricultural formulations require environmental stability, plant compatibility, target specificity, and cost-effective field delivery.

• Cosmetics: Cosmetic applications represent approximately 6% of application activity and are associated with antimicrobial protection, skin microbiome management, preservation, and specialized personal-care formulations. Peptides such as LL-37 are studied for antimicrobial and immunomodulatory properties, while synthetic peptide derivatives can be designed for improved stability. Cosmetic developers increasingly investigate ingredients that combine antimicrobial functionality with skin-supporting characteristics. Product formulation must consider pH, temperature, preservatives, packaging interactions, and compatibility with other active ingredients.

• Others: Other applications account for approximately 12% of the application structure and include medical-device coatings, research reagents, aquaculture, veterinary medicine, water treatment, biotechnology, and specialized biomaterials. Antimicrobial peptide coatings can help reduce microbial attachment to surfaces, while research-grade peptides are widely used in laboratory assays. Aquaculture represents an emerging opportunity because bacterial disease can affect fish and shellfish production. Veterinary applications include wound management and infection-control research. The diversity of these applications reduces dependence on a single commercial pathway and allows peptide manufacturers to develop specialized products.

•   
•   
  Download Free Sample to learn more about this report

    

ANTIMICROBIAL PEPTIDES MARKET REGIONAL INSIGHTS

• North America

North America accounts for 32% of the global Antimicrobial peptides market, supported by advanced biotechnology research, strong healthcare infrastructure, and increasing demand for novel anti-infective therapies. The United States is the major contributor due to extensive pharmaceutical development, clinical research activities, and investments in peptide-based therapeutics. Canada also supports regional growth through academic research and biotechnology innovation. Rising concerns regarding antimicrobial resistance, increasing focus on alternative treatment solutions, and growing collaborations between research institutions and pharmaceutical companies are driving the adoption of antimicrobial peptides across healthcare and research applications.

• Europe

Europe represents 27% of the global Antimicrobial peptides market, driven by strong pharmaceutical research capabilities, biotechnology advancements, and increasing focus on antimicrobial resistance management. Germany, the United Kingdom, France, Switzerland, and the Netherlands are key markets due to their established healthcare systems and life science industries. European research organizations are actively developing peptide-based solutions for infectious diseases, wound care, and therapeutic applications. Government-supported healthcare innovation, increasing clinical research investments, and demand for next-generation antimicrobial treatments are supporting market expansion across the region.

• Asia-Pacific

Asia-Pacific holds 25% of the global Antimicrobial peptides market, supported by expanding healthcare infrastructure, rising biotechnology investments, and increasing research activities in emerging economies. China, Japan, South Korea, India, and Singapore are major contributors due to growing pharmaceutical industries and advancements in biomedical research. Increasing prevalence of infectious diseases, rising healthcare spending, and government initiatives supporting drug discovery are creating new opportunities for antimicrobial peptide development. The region is also benefiting from increased collaborations between academic institutions, biotechnology firms, and pharmaceutical manufacturers.

• Middle East & Africa

Middle East & Africa contributes 9% of the global Antimicrobial peptides market, supported by improving healthcare systems, rising awareness of antimicrobial resistance, and investments in medical research facilities. Gulf countries such as Saudi Arabia and the UAE are emerging markets due to healthcare modernization programs and biotechnology initiatives. South Africa contributes through research activities and healthcare development projects. Growing demand for advanced infection management solutions, increasing disease prevention efforts, and expansion of pharmaceutical capabilities are gradually strengthening regional market opportunities.

• Rest of World

Rest of World represents 7% of the global Antimicrobial peptides market, with Latin America contributing significantly through increasing healthcare investments and pharmaceutical development activities. Brazil, Mexico, and Argentina are key markets supported by growing demand for innovative infection treatment solutions and expanding medical research capabilities. Rising awareness of antimicrobial resistance, improvements in healthcare access, and increasing collaborations with global biotechnology companies are supporting market growth. The region offers opportunities for peptide-based therapies as healthcare systems continue adopting advanced treatment technologies.

KEY INDUSTRY PLAYERS

The global Antimicrobial peptides market consists of leading pharmaceutical companies, biotechnology firms, peptide synthesis specialists, and antimicrobial research organizations focused on developing novel peptide-based solutions for drug-resistant infections and other applications. Companies such as Merck & Co., Inc., Roche Holding AG, and GenScript Biotech Corporation are strengthening their market presence through antimicrobial discovery, peptide development, synthetic biology, and advanced research capabilities. InvivoGen, Sigma-Aldrich Corporation, and EnBiotix, Inc. are supporting antimicrobial peptide research through specialized peptide products, laboratory technologies, and innovative drug-discovery platforms.

Biotechnology and peptide specialists including Shenzhen Sunsmile Biotechnology Co., Ltd., Linzhou Sinagri Yingtai Biological Peptide Co., Ltd., Abeona Therapeutics Inc., and Peptobiotics are focusing on peptide synthesis, recombinant antimicrobial peptide production, therapeutic development, animal health, and biotechnology applications. Bachem Holding AG, PolyPeptide Group, AnaSpec, Inc., and Novabiotics Ltd. are contributing through peptide manufacturing, peptide research, and antimicrobial technology development. The competitive landscape is driven by increasing antimicrobial resistance, advances in peptide engineering, AI-assisted peptide discovery, recombinant production, targeted delivery technologies, and growing demand for alternatives to conventional antibiotics across pharmaceutical, agriculture, animal feed, food, and biotechnology applications.

LIST OF TOP ANTIMICROBIAL PEPTIDES COMPANIES

• Merck & Co., Inc.
• Roche Holding AG
• GenScript Biotech Corporation
• Sigma-Aldrich Corporation
• InvivoGen
• EnBiotix, Inc.
• Shenzhen Sunsmile Biotechnology Co., Ltd.
• Linzhou Sinagri Yingtai Biological Peptide Co., Ltd.
• Abeona Therapeutics Inc.
• AnaSpec, Inc.
• AMP Biotech
• Phoenix Biotechnology, Inc.
• Novabiotics Ltd.
• Bachem Holding AG
• PolyPeptide Group
• Thermo Fisher Scientific Inc.
• Peptilogics, Inc.
• Amferia AB
• Xellia Pharmaceuticals
• Peptobiotics

MARKET LEADERSHIP MATRIX: ANTIMICROBIAL PEPTIDES MARKET

LEADER INSIGHTS

• GenScript Biotech Corporation: Sherry Shao, Rotating CEO, highlighted GenScript’s long-term growth outlook through continued innovation across gene, protein, and emerging modalities, alongside expanded customer reach, partnerships, automation, and digitalization. These priorities support broader adoption of advanced biotechnology and strengthen opportunities for peptide-based research and development, including antimicrobial peptide applications. (Published: March 16, 2026 | Source: https://www.genscript.com/genscript-biotech-announces-2025-results.html)

• Roche Holding AG: Thomas Schinecker, CEO of Roche Group, emphasized continued momentum in pharmaceutical innovation and the company’s focus on addressing significant unmet healthcare needs through advancing pipeline technologies and diagnostics. The emphasis on R&D-driven innovation and new therapeutic solutions supports longer-term opportunities for advanced antimicrobial and biotechnology applications. (Published: April 23, 2026 | Source: https://www.roche.com/investors/updates/inv-update-2026-04-23)

• Merck & Co., Inc.: Robert M. Davis, Chairman, CEO and President, continues to lead Merck’s strategy around innovative healthcare solutions and global pharmaceutical development. The company’s broad research and commercial capabilities provide a strong platform for addressing infectious-disease challenges and supporting future opportunities for novel antimicrobial technologies. (Executive leadership verified in the 2025 Annual Report; no sufficiently specific recent executive statement directly addressing antimicrobial peptide market growth was identified.)

INVESTMENT ANALYSIS AND OPPORTUNITIES

Investment activity in the Antimicrobial peptides market is increasingly concentrated on AI-enabled discovery, peptide synthesis, targeted delivery, antimicrobial-resistance programs, and manufacturing technologies. North America represented 38.61% of market activity in 2025, making the region a major destination for research investment. Federal antimicrobial programs have supported more than $2.7 billion cumulatively across antimicrobial products and development initiatives. AI platforms are creating additional opportunities by reducing early-stage screening requirements. One 2023 research platform evaluated 500 computationally selected candidates and identified 30 functional antimicrobial peptides, demonstrating the potential for higher-throughput discovery.

Investment opportunities also exist in recombinant peptide manufacturing, peptide stabilization, topical delivery, wound-care formulations, medical-device coatings, agricultural biocontrol, and animal-feed applications. Approximately 52.26% of market activity is associated with pharmaceuticals, indicating that therapeutic development remains the principal investment area. However, non-pharmaceutical applications can diversify commercial exposure. Investors are increasingly evaluating companies with proprietary peptide libraries, AI-driven design platforms, scalable synthesis technologies, and strong intellectual-property portfolios. Partnerships between pharmaceutical companies and biotechnology firms can reduce development bottlenecks.

NEW PRODUCT DEVELOPMENT

New product development in the Antimicrobial peptides market is focused on improving antimicrobial potency, selectivity, stability, delivery, and resistance profiles. A 2024 research program developed DTr18-dab, a synthetic antimicrobial peptide engineered using noncanonical amino acids. The peptide demonstrated broad-spectrum antibacterial activity, biofilm activity, serum activity, and activity against colistin-resistant bacteria. These characteristics illustrate the direction of next-generation peptide development, where a single candidate is optimized across multiple performance parameters rather than antimicrobial potency alone.

AI is also changing product development. In 2024, an AI foundation-model platform generated 18 novel antimicrobial peptide candidates in 11 days, with 94.4% showing notable antibacterial activity during validation. Two candidates demonstrated approximately 100-fold bacterial-load reduction in an animal model. Another 2023 platform used cell-free protein synthesis to produce and test computationally designed peptides in less than 24 hours. Product developers are also investigating peptide combinations with conventional antibiotics, biofilm-disrupting formulations, inhaled delivery, topical wound products, and antimicrobial coatings.

FIVE RECENT DEVELOPMENTS

• December 2023: Invaio Sciences acquired Peptyde Bio to strengthen its antimicrobial peptide-based crop-protection platform. The acquisition added Peptyde Bio’s peptide discovery capabilities and intellectual property to Invaio’s biological crop-protection portfolio. The initiative focused on identifying antimicrobial peptides that could target agricultural pathogens while reducing dependence on conventional chemical crop-protection products, strengthening opportunities for peptide-based biological solutions in sustainable agriculture.
• April 2024: Peptobiotics secured $6.2 million in Series A financing to commercialize recombinant antimicrobial peptide technology for aquaculture. The company planned to use the investment to expand production and advance peptide-based alternatives to conventional antibiotics. Its platform uses synthetic biology and precision fermentation to produce recombinant antimicrobial peptides designed to address bacterial diseases in aquaculture while supporting antibiotic-reduction strategies and sustainable production.
• July 2024: Roche advanced zosurabalpin as a novel macrocyclic peptide antibiotic targeting drug-resistant Acinetobacter baumannii. The program targets the LptB₂FGC lipopolysaccharide transport complex, providing a mechanism distinct from established antibacterial classes. Preclinical research demonstrated activity against highly drug-resistant bacterial isolates, strengthening Roche’s development strategy for difficult-to-treat Gram-negative infections and highlighting macrocyclic peptides as an emerging antimicrobial technology.
• January 2025: Roche updated its development pipeline to identify zosurabalpin as an antibiotic macrocyclic peptide in clinical development. The company’s pipeline update highlighted zosurabalpin as a novel antibiotic candidate for bacterial infections and identified its macrocyclic peptide classification. The development strengthened Roche’s position in next-generation antimicrobial research and demonstrated continued pharmaceutical investment in peptide-based approaches for drug-resistant Gram-negative bacterial infections.
• February 2025: Roche advanced its zosurabalpin development program following publication of clinical findings supporting its novel antibiotic mechanism. The program focused on infections caused by Acinetobacter baumannii, with zosurabalpin designed to inhibit lipopolysaccharide transport. The development reinforced the strategic importance of macrocyclic peptide antibiotics and supported continued clinical evaluation of a new antimicrobial mechanism against resistant Gram-negative pathogens.

ANTIMICROBIAL PEPTIDES MARKET REPORT COVERAGE

The Antimicrobial peptides market report covers product development, peptide sources, applications, regional performance, competitive positioning, innovation, investment opportunities, and market dynamics across major geographic regions. The analysis evaluates recombinant and natural antimicrobial peptides and examines pharmaceutical, animal-feed, food-additive, agriculture, cosmetics, and other applications. Pharmaceutical applications represented 52.26% of market activity in 2025, while natural-source peptides accounted for 38.44%. The report also considers topical, systemic, localized, and research-oriented delivery approaches, with topical administration representing 34.64% of market activity.

Geographically, the report covers North America, Europe, Asia-Pacific, and Middle East & Africa. North America represented 38.61% of the market in 2025, Europe approximately 29%, Asia-Pacific approximately 24%, and Middle East & Africa approximately 8%. Competitive coverage includes Merck & Co., Inc., Roche Holding AG, Shenzhen Sunsmile Biotechnology Co., Ltd., Linzhou Sinagri Yingtai Biological Peptide Co., Ltd., Abeona Therapeutics Inc., InvivoGen, GenScript Biotech Corporation, EnBiotix, Inc., and Sigma-Aldrich Corporation. The report evaluates antimicrobial-resistance pressure, AI-driven peptide discovery, recombinant production, peptide stabilization, biofilm control, and targeted delivery.